PKN2 and neoplasm: Encouragingly, these non-selective inhibitors are known to suppress PSC myofibroblast function (Masamune et al., 2003; Whatcott et al., 2017) and show promising pre-clinical activity in mouse PDAC models (El Fitori et al., 2007; Vennin et al., 2017, 2020; Whatcott et al., 2017), where PKN2 is likely to have roles in both stromal and tumor compartments; the contribution of PKN2 targeting to the in vivo effects of these inhibitors remains to be addressed.